We have found that resveratrol (trans-3,4 0 ,5-trihydroxystilbene) induced apoptosis in multiple myeloma (MM) and T-cell leukemia cells through coclustering of Fas/ CD95 death receptor and lipid rafts, whereas normal lymphocytes were spared. Tumor necrosis factor-related apoptosis-inducing ligand receptors, Fas-associated death domain-containing protein (FADD), procaspase-8, procaspase-10, c-Jun amino-terminal kinase and Bid were also recruited into lipid rafts on resveratrol incubation with MM and T-cell leukemia cells. Raft disruption inhibited resveratrol-induced apoptosis. Bcl-X L overexpression prevented resveratrol-induced disruption of mitochondrial transmembrane potential (DW m ) and apoptosis. A FADD dominant-negative mutant, that blocked Fas/CD95 downstream signaling, precluded resveratrolinduced DW m loss and apoptosis, indicating a sequence of Fas/CD95 signaling-mitochondrion in the apoptotic response triggered by resveratrol. Cells deficient in Fas/CD95 did not undergo resveratrol-induced apoptosis. Pretreatment of MM cells with interferon-g upregulated Fas/CD95 and caspase-8, and potentiated resveratrolinduced apoptosis. Our data indicate that recruitment of Fas/CD95 death receptor and downstream signaling molecules into lipid rafts, followed by DW m disruption, underlies the apoptotic action of resveratrol in MM and T-cell leukemic cells. Combination of resveratrol with perifosine or bortezomib potentiated the apoptotic response induced by each single drug. These results also highlight the role of recruitment of Fas/CD95 signaling in lipid rafts in antimyeloma and antileukemia chemotherapy.
Introduction
Hematopoietic malignancies are frequently characterized by a defective apoptosis. Multiple myeloma (MM) is a currently incurable B-cell malignancy characterized by the accumulation of plasma cells with a low proliferative index and an extended life span in the bone marrow (Barille-Nion et al., 2003; Lonial, 2007) . Thus, a therapeutic potential for MM and additional hematological cancers may lie in potentiating apoptosis (Mollinedo and Gajate, 2006a, b) .
A new framework in apoptosis regulation is mediated by coclustering of Fas/CD95 death receptor and lipid rafts (Gajate and Mollinedo, 2001; Gajate et al., 2009a) , leading to the concentration of Fas/CD95-downstream signaling apoptotic molecules in membrane rafts that trigger a cell death response (Gajate et al., 2004 (Gajate et al., , 2009b . This Fas/CD95-raft coclustering plays a key role in the proapoptotic action of some anticancer drugs, including edelfosine, perifosine and aplidin (Gajate and Mollinedo, 2001 Gajate et al., 2004; Nieto-Miguel et al., 2006; Mollinedo and Gajate, 2006a; Nieto-Miguel et al., 2008) . Chemotherapeutic agent-induced recruitment of Fas/CD95 and downstream signaling molecules in membrane rafts leads to the generation of the deathinducing signaling complex (DISC) in lipid rafts, made up of Fas/CD95, Fas-associated death domain-containing protein (FADD) and procaspase-8 (Gajate and Mollinedo, 2007; Gajate et al., 2009a) , and eventually to apoptosis. Furthermore, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are also translocated into rafts following incubation with distinct anticancer drugs (Gajate and Mollinedo, 2005; Gajate and Mollinedo, 2007) .
Resveratrol (trans-3,4 0 ,5-trihydroxystilbene) is a polyphenolic phytoalexin, abundant in grapes, berries and peanuts, that inhibits the growth of a wide variety of tumor cells and shows chemoprotective properties (Jang et al., 1997; Aziz et al., 2003) . Resveratrol has been shown to induce redistribution of Fas/CD95 and TRAIL receptors in lipid rafts in colon carcinoma cells (Delmas et al., 2003 (Delmas et al., , 2004 . Resveratrol induces apoptosis in hematological malignant cells, including MM cells (Bhardwaj et al., 2007) . On these grounds, we investigated the role of Fas/CD95 and lipid raft coclustering in the antimyeloma and antileukemic action of resveratrol.
Results

Resveratrol induces apoptosis in MM and T-cell leukemia cells, although spares normal lymphocytes
We found that resveratrol induced apoptosis in the human T-cell leukemia Jurkat cell line as well as in the human MM cell lines MM144 and MM1S in a doseresponse manner (Figures 1a-c) . This apoptotic response was further assessed by caspase-3 activation and cleavage of the typical caspase-3 substrate poly(ADPribose) polymerase (PARP), by using a polyclonal anticaspase-3 antibody that recognized the active 20-and 17-kDa subunits of caspase-3, and an anti-PARP monoclonal antibody that detected both the 116-kDa intact form and the 85-kDa cleaved form of PARP (Figure 1b) . Resveratrol also induced apoptosis in primary cultures of MM cells derived from patients (Figure 1d ), whereas normal mononuclear cells from the same patients as well as peripheral blood normal lymphocytes from healthy volunteers were spared (o5% apoptosis). These data suggest a rather selective action of resveratrol against MM and T-cell leukemia cells.
Resveratrol-induced apoptosis in MM and T-cell leukemia cells is mediated by clustering of Fas/CD95 in lipid rafts
Following a time-course analysis, we found that 50 mM resveratrol triggered apoptosis after 15-20 h incubation Fas/CD95 signaling and rafts in resveratrol action M Reis-Sobreiro et al in Jurkat and MM144 cells (data not shown). Resveratrol induced coclustering of rafts and Fas/CD95 in both Jurkat and MM144 cells (Figure 2a) , as assessed by using the raft marker fluorescein isothiocyanate (FITC)-labeled cholera toxin (CTx) B subunit that binds ganglioside GM1 (Schon and Freire, 1989) , mainly found in rafts (Harder et al., 1998) , and a specific anti-Fas/CD95 antibody. Disruption of lipid rafts by cholesterol depletion through methyl-b-cyclodextrin (MCD) treatment (Christian et al., 1997; Gajate and Mollinedo, 2001 ) inhibited resveratrol-induced formation of Fas/CD95 clusters (data not shown) and apoptosis in both T-cell leukemia and MM cells (Figures 2b and c) . No Fas/CD95-raft coclusters were Fas/CD95 signaling and rafts in resveratrol action M Reis-Sobreiro et al observed after resveratrol incubation with normal peripheral blood lymphocytes (data not shown). These results indicate that coclustering of Fas/CD95 and membrane rafts mediates the apoptotic action of resveratrol in MM and T-cell leukemia cells.
Resveratrol induces translocation of death receptors and downstream molecules into lipid rafts in MM and T-cell leukemia cells The above Fas/CD95 and raft coclustering was further confirmed by isolation of membrane rafts from Jurkat and MM144 cells, untreated and treated with resveratrol ( Figure 3 ). Lipid rafts were isolated based on their insolubility in Triton X-100 lysis buffer at 4 1C and fractionated by discontinuous sucrose gradient centrifugation (Gajate and Mollinedo, 2001 ). GM1-containing lipid rafts, at the upper part (mostly in fractions 3-5) of the sucrose gradient (Figure 3 ), were identified using CTx conjugated to horseradish peroxidase (Gajate and Mollinedo, 2001) . Fas/CD95 was present in the non-raft fractions (fractions 10-12) of the sucrose gradient in untreated Jurkat and MM144 cells, but resulted dramatically translocated to the raft fractions on resveratrol treatment for 15 h (Figure 3 ). MM144 cells express the TRAIL receptors DR4 and DR5, whereas Jurkat cells only express DR5, and all these TRAIL receptors were also translocated to rafts in both cell types following resveratrol treatment, although to a lesser extent than Fas/CD95 (Figure 3 ). Death receptor downstream signaling molecules FADD, procaspase-8 and procaspase-10 were also translocated into rafts ( Figure 3 ). Interestingly, a portion of the active cleaved caspase-8 and caspase-10 forms were also found in rafts following resveratrol treatment (Figure 3 ), suggesting that triggering of apoptosis is initiated at the membrane rafts. These data show that all the constituents of DISC, namely Fas/CD95, FADD and procaspase-8, are recruited into rafts; and this key apoptotic complex in death receptor signaling is activated in the membrane raft. We also found that Bid, which acts as a bridge between Fas signaling and mitochondria (Luo et al., 1998) , was translocated into rafts following treatment of Jurkat and MM144 cells with resveratrol ( Figure 3 ). In addition, c-Jun amino-terminal kinase (JNK) was recruited into lipid rafts on resveratrol incubation (Figure 3 ). Our results show that resveratrol induces a reorganization of the raft protein content, translocating apoptotic proteins to these detergent-insoluble membrane domains in hematological cancer cells. (Bennett et al., 2001 ) inhibited resveratrolinduced apoptosis to a rather variable degree (22-59% inhibition; Figure 4a ). Preincubation of MM144 cells with 20 mM SP600125 for 1 h inhibited resveratrol-induced JNK activation to more than 70% (data not shown), but only 33% inhibition was observed in resveratrol-induced apoptosis ( Figure 4a ). This partial inhibition suggests that JNK is acting in parallel to additional signaling pathways to increase cell death, but it does not seem to play an essential role in the apoptosis outcome. for 15 h were lysed in 1% Triton X-100 and fractionated by centrifugation on a discontinuous sucrose density gradient. An equal volume of each collected fraction was subjected to SDSpolyacrylamide gel electrophoresis (PAGE) before analysis of the indicated proteins using specific antibodies. The migration positions of the 55-kDa procaspase-8 and the cleaved p18 product, as well as of the 58-kDa procaspase-10 and the cleavage products are denoted. Location of GM1-containing lipid rafts was determined using cholera toxin (CTx) B subunit conjugated to horseradish peroxidase. (b) Untreated MM144 cells (control) and MM144-treated cells treated with 50 mM resveratrol (RESV) for 15 h were lysed and analysed by western blotting as above. Representative blots of three separate experiments are shown. Fas/CD95 signaling and rafts in resveratrol action M Reis-Sobreiro et al reported (Gajate and Mollinedo, 2007) . Treatment of MM144-Neo cells with resveratrol led to apoptosis ( Figure 4b ) and mitochondrial transmembrane potential (DC m ) disruption (Figures 4c and d) . However, overexpression of Bcl-X L by gene transfer in MM144 cells prevented both resveratrol-induced apoptosis ( Figure 4b ) and DC m loss (Figures 4c and d) . These data indicate that mitochondria are involved in resveratrol-induced MM cell death.
As shown in Figure 4d , untreated cells showed high DC m (DiOC 6 (3) high ) and low levels of intracellular reactive oxygen species (ROS; HE-Eth) high cells after resveratrol incubation (Figure 4c ). These results suggest that DC m dissipation was critical for resveratrol-induced apoptosis in MM and T-cell leukemia cells, and that a minor portion of ROS may originate from additional sources, apart from mitochondria that plays no essential role in resveratrol-induced apoptosis.
Fas/CD95 signaling and mitochondrion connection in resveratrol-induced apoptosis As the above data showed that both Fas/CD95 and mitochondria signaling were involved in resveratrolinduced apoptosis in hematological cancer cells, and the Fas/CD95-mitochondrion bridging molecule Bid was recruited into lipid rafts together with Fas/CD95 downstream molecules (Figure 3 ), we wondered whether Fas/CD95 and mitochondrial apoptotic signaling routes were acting in conjunction. Using stable transfection in Jurkat cells of a dominant-negative form of the FADD adapter protein (FADD-DN), which lacks the death effector domain and blocks Fas/CD95 signaling (Hofmann et al., 2001), we found that blockade of Fas/CD95 downstream signaling prevented both DC m loss (Figures 5a and b) and apoptosis ( Figure 5c ). In addition, Fas/ CD95-deficient Jurkat cells, that preserved the expression of functional tumor necrosis factor receptor 1 and DR5 (Gajate et al., 2004) , were rather resistant to undergo apoptosis on resveratrol treatment (Figure 5d ). These data suggest a prevailing role of Fas/CD95 in resveratrol-induced DC m dissipation and apoptosis in Jurkat cells.
Interferon-g upregulates Fas/CD95 and caspase-8, potentiating resveratrol-induced apoptosis Following pretreatment of MM cells with interferon (IFN)-g, we found an increase in both Fas/CD95 and procaspase-8 protein levels by western blot (Figure 6a ). We found that MM cells pretreated with IFN-g showed an increase in the cell surface expression of Fas/CD95 (Figure 6b ) and were more sensitive to the apoptotic action of resveratrol (Figure 6c ). These data suggest that an increase in Fas/CD95 potentiates the apoptotic response of resveratrol.
Resveratrol induces apoptosis and Fas/CD95-raft coclusters in Fas/CD95-resistant U266 cells The MM cell line U266 expresses Fas/CD95, but addition of the agonistic anti-Fas/CD95 antibody CH11 induces less than 5% apoptosis (Shima et al., 1995; Westendorf et al., 1995) . We found that U266 cells expressed Fas/CD95, DR4 and DR5 at their cell surface (Figure 7a) , and underwent apoptosis following resveratrol treatment (Figure 7b ). Interaction of Fas/CD95 with either the agonistic anti-Fas/CD95 antibody CH11 or the physiological ligand FasL/CD95L did not induce apoptosis in U266 cells (Figure 7c ). Thus, U266 cells are deficient in mounting a Fas/CD95-FasL/CD95L interaction-dependent apoptotic response. Preincubation of U266 cells with the blocking SM1/23 anti-Fas/CD95 antibody, which abrogates Fas/CD95-FasL/CD95L-mediated killing (Gajate et al., 2000a) , failed to inhibit resveratrol-induced apoptosis (Figure 7c ), indicating that resveratrol-induced apoptosis is not mediated by FasL/CD95L. The combination of resveratrol with CH11 or FasL/CD95L slightly potentiated the cell death outcome (Figure 7c ), suggesting that resveratrol might partially circumvent the block in mounting a Fas/ CD95-mediated apoptotic signal. Resveratrol induced a potent coclustering of rafts and Fas/CD95 in U266 cells (Figure 7d ). However, disruption of rafts by cholesterol depletion with MCD inhibited only weakly resveratrolinduced apoptosis in U266 cells (23.4 ± 2.4 versus 16.8 ± 2.3 apoptosis in untreated and MCD-pretreated cells, respectively, and then incubated with 70 mM resveratrol for 24 h, n ¼ 4). Thus, these data suggest that resveratrol is effective in promoting coclusters of Fas/CD95 and rafts, but additional mechanisms must play a role in the induction of apoptosis by resveratrol in U266 cells.
Combination of resveratrol with perifosine or bortezomib potentiates apoptosis
We next analysed the putative potentiation of apoptosis as a result of combining resveratrol with additional drugs acting through similar or distinct mechanisms of action. Perifosine has been reported to induce apoptosis in MM cells through Fas/CD95-raft coclustering (Gajate and Mollinedo, 2007) , and its antimyeloma activity is being tested in clinical trials (Mollinedo, 2007) . The proteasome inhibitor bortezomib is currently used in clinic against MM and other hematological malignancies (Orlowski and Kuhn, 2008) . We found that the combination of edelfosine and perifosine showed an additive effect, whereas the combination of resveratrol and bortezomib had a synergistic effect on apoptosis (Figures 8a and b) . The additive effect observed following treatment with resveratrol and perifosine suggests that both drugs share, at least in part, similar Fas/CD95 signaling and rafts in resveratrol action M Reis-Sobreiro et al modes of action. These data would support a mechanism of action mediated by Fas/CD95-raft coclustering. Unlike other assayed cells, U266 cells showed a rather poor additive effect between resveratrol and perifosine (Figure 8a ), suggesting that the raft-mediated process is not so critical in cell death induction in this particular cell line. The synergistic effect observed following treatment with resveratrol and bortezomib indicates that both substances act through different mechanisms of action. The combined treatment of resveratrol and bortezomib highly potentiated the apoptosis outcome exerted by each individual drug (Figures 8a and b) . Thus, the raft-mediated mechanism of action of resveratrol might be of interest for combination therapy in the treatment of blood malignancies.
Discussion
The data reported here show that resveratrol induces apoptosis in MM and T-cell leukemia cells through the recruitment of Fas/CD95 death receptor and downstream signaling molecules into lipid rafts. Our results demonstrate that Fas/CD95 signaling and mitochondria are required for resveratrol-induced apoptosis, and there is a sequence of Fas/CD95-mitochondrion in the signaling pathway underlying the apoptotic response triggered by resveratrol in hematological cancer cells. A putative linker between Fas/CD95 signaling and mitochondrion in resveratrol action might be the translocation of Bid to lipid rafts together with Fas/CD95 signaling molecules. Thus, our present data Fas/CD95 signaling and rafts in resveratrol action M Reis-Sobreiro et al square with the following sequence of events in MM and T-cell leukemia cells that lead to resveratrol-induced apoptosis: coclustering of Fas/CD95 and lipid raftsrecruitment of Fas/CD95 downstream signaling molecules to membrane rafts-Bid translocation to rafts-DC m disruption-apoptosis (Figure 9 ). Interference at critical stages of the above scheme, such as disruption of lipid rafts, inhibition of Fas/CD95 signaling by FADD-DN transfection and mitochondria protection by overexpression of Bcl-X L , prevented resveratrol-induced apoptosis ( Figure 9 ). As the blockade of Fas/CD95 downstream signaling by FADD-DN overexpression abrogates both DC m loss and apoptosis, mitochondrial events are downstream of Fas/CD95 signaling in resveratrol-mediated apoptosis. Our data demonstrate that membrane rafts, Fas/CD95 signaling and mitochondria are crucial players in the apoptotic outcome delivered by resveratrol in MM and T-cell leukemia cells.
Resveratrol is effective in inducing the recruitment of Fas/CD95 in raft clusters even in U266 cells, which are resistant to undergo apoptosis on Fas/CD95 stimulation by either FasL/CD95L or agonistic anti-Fas/CD95 antibody. We have previously found that induction of clustering of Fas/CD95 in rafts leads to death receptor activation, independently of its ligand, even in cells that are resistant to undergo apoptosis following Fas/CD95 stimulation through its interaction with FasL/CD95L or agonistic anti-Fas/CD95 antibody (Gajate et al., 2000a) . Thus, Fas/CD95 activation by its clustering in rafts seems to be more potent than the receptor activation elicited by its physiological ligand. However, the fact that raft disruption only inhibits about 28% of resveratrol-induced apoptosis in U266 cells suggests that additional mechanisms leading to resveratrolmediated killing are triggered in these particular cells. One of these mechanisms has been reported to involve downregulation of STAT3 and nuclear factor-kB (Bhardwaj et al., 2007) .
The present data also show that TRAIL receptors are translocated, in addition to Fas/CD95, into rafts following resveratrol treatment of MM and T-cell leukemic cells. This recruitment and concentration of death receptors in specific domains of the cell surface has clear clinical consequences as it might sensitize cancer cells to death receptor ligands (Gajate and Mollinedo, 2007) . This is of particular interest for TRAIL-mediated therapy, because TRAIL is under ongoing clinical trials (Ashkenazi et al., 2008) . The recruitment of death receptors and downstream signaling in membrane rafts promoted by resveratrol treatment may underlie previous observations reporting that this polyphenol sensitizes different cancer cell types to death receptor-mediated apoptosis (Fulda and Debatin, 2005; Gill et al., 2007) .
The findings reported here underline the role of Fas/ CD95 recruitment into lipid rafts as a major mechanism in anticancer chemotherapy for the treatment of hematological malignancies. We have recently found that a number of anticancer drugs, including edelfosine, perifosine and aplidin, induce apoptosis in hematological cancer cells by bringing together Fas/CD95 and downstream signaling molecules in membrane rafts (Gajate and Mollinedo, 2001 Gajate et al., 2004) .
Our data show that IFN-g enhances the apoptotic response induced by resveratrol in hematological cancer cells, likely through an increase in Fas/CD95 and procaspase-8 levels. On these grounds, the present data suggest that resveratrol is not only effective in killing by itself hematological cancer cells, but also it might be a valuable drug in combination therapy, in particular with agents modulating or activating death receptor signaling. The combination of resveratrol and perifosine, which has been shown to act through raft-Fas/CD95 coclustering (Gajate and Mollinedo, 2007) , resulted in an additive effect, suggesting a shared mode of action for both drugs. In addition, the combination of resveratrol with the proteasome inhibitor bortezomib led to a synergistic apoptotic response. It is tempting to speculate that a putative interaction between raftmediated processes triggered by resveratrol and proteasome inhibition might lead to a potent cell death response. Two naturally occurring resveratrol oligomers, eviniferin and miyabenol C, have been shown to promote apoptosis in lymphoid and myeloid cell lines at lower doses than resveratrol (Barjot et al., 2007) . Further investigation on the mode of action of these natural oligomers might set new frameworks for cancer treatment.
The mechanistic findings reported here suggest that resveratrol may have a potential in the treatment of MM and T-cell leukemia, and highlight the role of recruitment of Fas/CD95 signaling in lipid rafts in antimyeloma and antileukemia chemotherapy.
Materials and methods
Reagents
Resveratrol (Sigma, St Louis, MO, USA) was prepared as a 100 mM stock solution in dimethylsulfoxide (DMSO). Pancaspase inhibitor z-VAD-fmk (Alexis Biochemicals, Lausen, Switzerland), caspase-8 inhibitor z-IETD-fmk (Calbiochem, San Diego, CA, USA), caspase-10 inhibitor z-AEVD-fmk (R&D Systems, Minneapolis, MN, USA) and JNK inhibitor SP600125 (Calbiochem) were prepared as 10 or 20 mM stock solutions in DMSO. Velcade (bortezomib) was from Millenium Pharmaceuticals (Cambridge, MA, USA).
Cell culture
The human acute T-cell leukemia Jurkat cell line and the human MM cell lines MM1S, MM144 and U266 were grown in RPMI-1640 culture medium supplemented with 10% heatinactivated fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml of penicillin and 100 mg/ml streptomycin at 37 1C in humidified 95% air and 5% CO 2 . The Jurkat FADD-DN cell line is a Jurkat-derived clone stably transfected with a pcDNA3 expression vector encoding a dominant-negative form of the FADD protein (Hofmann et al., 2001) , and was maintained in complete RPMI-1640/10% FBS medium containing 200 mg/ml G418. Jurkat cells were also transfected with control pcDNA3 empty vector using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Fas-deficient Jurkat cells were generated following protracted cultures (over 10 months) of parental Jurkat cells (Gajate and Mollinedo, 2005) .
Heparinized bone marrow aspirates, obtained from patients with newly diagnosed MM and after signing informed consent, were provided by the Hematology Department of the University Hospital (Salamanca, Spain). The study was approved by the Ethics Committee of the University Hospital. Purified CD138 þ tumor cells (>95% plasma cells) and CD138
À nontransformed cells were isolated as previously described (Gajate and Mollinedo, 2007) , resuspended in RPMI-1640/10% FBS medium, and used immediately for experiments.
Normal peripheral blood lymphocytes from healthy volunteers were isolated as previously described (Cabaner et al., 1999) . Fas/CD95 signaling and rafts in resveratrol action M Reis-Sobreiro et al
Cell transfection with bcl-x L MM144 cells were transfected by electroporation with the SFFV-Neo expression vector containing the human bcl-x L open reading frame driven by the long terminal repeat of the splenic focus-forming virus (pSFFV-bcl-x L ) as previously described (Gajate and Mollinedo, 2007) . As a control, transfection was performed with empty SFFV-Neo plasmid. Stable transfectants were selected with 1 mg/ml G418.
Apoptosis assay
Quantitation of apoptotic cells was calculated by flow cytometry as the percentage of cells in the sub-G 1 region (hypodiploidy) in cell-cycle analysis as previously described (Gajate et al., 2000b) . The possible implication of Fas/CD95-FasL/CD95L interaction in resveratrol-induced apoptosis was evaluated by using the blocking anti-Fas/CD95 SM1/23 IgG 2b monoclonal antibody (Bender MedSystems, Vienna, Austria) as described previously (Gajate et al., 2003) .
Confocal microscopy
Untreated and resveratrol-treated cells (1 Â 10 6 ) were settled onto slides coated with poly-L-lysine, fixed in 4% formaldehyde, and then incubated with anti-human Fas/CD95 SM1/23 monoclonal mouse antibody (diluted 1:150 in phosphatebuffered saline (PBS); Bender MedSystems) for 1 h at room temperature. Samples were washed with PBS and incubated for 1 h with CY3-conjugated sheep anti-mouse antibody (diluted 1:150 in PBS; Jackson ImmunoResearch, West Grove, PA, USA), washed with PBS and stained with 8 mg/ml FITC-CTx B subunit (Sigma) as a raft marker. Samples were then analysed by confocal microscopy using a Zeiss LSM510 laser scan confocal microscope (Oberkochen, Germany) for membrane raft and protein visualization as described (Gajate and Mollinedo, 2001) . Colocalization assays were analysed by excitation of the corresponding fluorochromes in the same section. Negative controls, lacking the primary antibody or using an irrelevant antibody, showed no staining.
Cholesterol depletion
For cholesterol depletion, 7 Â 10 5 cells were washed in serumfree medium three times, pretreated with 2.5 mg/ml MCD for 30 min at 37 1C in serum-free medium. Cells were then washed three times with PBS and resuspended in complete culture medium before resveratrol addition.
Lipid raft isolation
Lipid rafts were isolated by using lysis conditions and centrifugation on discontinuous sucrose gradients as previously reported (Gajate and Mollinedo, 2001 ). Twelve fractions (1 ml each) were colleted from the top of the gradient. To determine the location of lipid rafts and distinct proteins in the discontinuous sucrose gradient, 20 ml of the individual fractions were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and immunoblotted as described previously Mollinedo, 2001, 2007) . After blocking for 1 h at room temperature with 5% powdered defatted milk in TBST (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.05% Tween-20), blots were incubated for 1 h at room temperature or overnight at 4 1C with the following specific antibodies: C-20 anti-48-kDa Fas/CD95 rabbit polyclonal antibody (1:1000 in TBST; Santa Cruz Biotechnology, Santa Cruz, CA, USA); N-19 anti-56-kDa DR4 goat polyclonal antibody (1:500 in TBST; Santa Cruz Biotechnology); N-19 anti-48-kDa DR5 goat polyclonal antibody (1:500 in TBST; Santa Cruz Biotechnology); anti-29-kDa FADD monoclonal antibody (clone-1; 1:250 in TBST; BD Transduction Laboratories, Lexington, KY, USA); Ab-3 anti-55-kDa procaspase-8 monoclonal antibody (1:500 in TBST; Oncogene Research Products, Cambridge, MA, USA); T-16 anti-18-kDa caspase-8 (1:500 in TBST; Santa Cruz Biotechnology); anti-58-kDa procaspase-10 polyclonal rabbit antibody (1:500 in TBST; Oncogene Research Products) that recognizes also the 40-, 23-and 17-kDa proteolytic fragments of caspase-10 on activation; C-17 anti-46-kDa JNK1 polyclonal rabbit antibody (1:500 in TBST; Santa Cruz Biotechnology) that reacts with both JNK1 and JNK3 isoforms leading to the two bands observed by western blotting; N-19 anti-23-kDa Bid goat polyclonal antibodies (1:500 in TBST; Santa Cruz Biotechnology). Antibody reactivity was monitored with biotinylated anti-rabbit, antimouse or anti-goat immunoglobulin G (IgG), using an enhanced chemiluminescence detection system (Amersham Biociences). The location of GM1-containing lipid rafts was determined using CTx B subunit conjugated to horseradish peroxidase (1:500 in TBST; Sigma) as previously described (Gajate and Mollinedo, 2001 ).
Cytofluorimetric analysis of mitochondrial transmembrane potential and generation of reactive oxygen species To evaluate DC m and the generation of ROS, cells (10 6 /ml) were incubated in PBS with 20 nM 3,3 0 -dihexyloxacarbocyanine iodide (DiOC 6 (3)); green fluorescence; Molecular Probes, Leiden, The Netherlands) and 2 mM dihydroethidine (HE; red fluorescence after oxidation; Sigma) for 40 min at 37 1C, followed by analysis on a Becton Dickinson (San Jose, CA, USA) fluorescence-activated cell sorting FACSCalibur flow cytometer as previously described (Gajate et al., 2000b) .
IFN-g treatment
To examine the effect of IFN-g incubation on protein expression, 4-5 Â 10 6 cells were treated with 50 ng/ml IFN-g (Upstate Biotechnology, Lake Placid, NY, USA) in RPMI-1640/10% FBS complete culture medium for 24 or 48 h, and then cells were lysed with 60 ml of lysis buffer (20 mM Hepes, pH 7.5, 10 mM EGTA, 40 mM b-glycerophosphate, 1% NP-40, 2.5 mM MgCl 2 , 2 mM orthovanadate, 1 mM DTT) supplemented with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 20 mg/ml aprotinin, 20 mg/ml leupeptin). After 30 min on ice, solubilized proteins were obtained by microcentrifugation. Proteins (20 mg) were run on SDS-polyacrylamide gels under reducing conditions, transferred to nitrocellulose filters, blocked with 5% powdered defatted milk in TBST for 1 h at room temperature, and incubated for 1 h at room temperature or overnight at 4 1C with the following specific antibodies: C-20 anti-48-kDa Fas/CD95 rabbit polyclonal antibody (1:1000 dilution in TBST; Santa Cruz Biotechnology), Ab-3 anti-58-kDa caspase-8 monoclonal antibody (1:1000 dilution; Oncogene Research Products) or AC-15 anti-42-kDa b-actin monoclonal antibody (1:5000 dilution; Sigma). Antibody reactivity was monitored with biotinylated anti-rabbit or anti-mouse IgG using an enhanced chemiluminescence detection kit (Amersham Biosciences).
To analyse the effect of IFN-g on apoptosis, cells (4 Â 10 5 ) were pretreated with 50 ng/ml IFN-g in a final volume of 2 ml for 48 h in RPMI-1640/10% FBS complete culture medium before incubation with resveratrol. Then, the percentage of apoptotic cells was assessed by flow cytometry in cell-cycle analysis.
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